Ocata Therapeutics to Host Conference Call and Webcast to Provide Corporate Update for the Third Quarter of 2015
November 06 2015 - 3:30PM
Business Wire
Call Scheduled for Monday, November 9, 2015 at
8:30 A.M.
Ocata Therapeutics, Inc. (NASDAQ: OCAT), a leader in the field
of Regenerative Ophthalmology™ announced today that it will host a
conference call on Monday, November 9th, 2015 at 8:30 a.m. EST,
during which it will provide a corporate update for the third
quarter of 2015.
Interested parties may access the call live by dialing (888)
539-3679 (US) or (719) 325-2370 (international) and using
conference ID 1107447.
A live audio webcast of the presentation will be available via
the “Investor Relations” page of the Ocata website, www.ocata.com.
A replay of the webcast will be archived on Ocata’s website for 90
days.
About Ocata Therapeutics, Inc.
Ocata Therapeutics, Inc. is a clinical stage biotechnology
company focused on the development and commercialization of
Regenerative Ophthalmology therapeutics. Ocata’s most advanced
products are in clinical trials for the treatment of Stargardt’s
macular degeneration, dry age-related macular degeneration, and
myopic macular degeneration. Ocata’s intellectual property
portfolio includes pluripotent stem cell platforms – hESC and
induced pluripotent stem cell (iPSC) – and other cell therapy
research programs. For more information, visit www.ocata.com.
About Age-related Macular Degeneration
Age-related macular degeneration is the leading cause of vision
loss in people over the age of 50. Every year in the USA there are
1.8 million patients newly diagnosed with dry AMD which occurs when
light-sensitive photoreceptor cells in the macula, located in the
center of the retina, slowly break down, causing vision loss as a
result. Photoreceptor breakdown is a consequence of loss or damage
to the RPE layer. As the disease progresses, patients may have
difficulty reading and recognizing faces. There is currently no
proven medical therapy for dry AMD and the projected number of
people worldwide with age-related macular degeneration in 2020 is
196 million, increasing to 288 million in 2040 underscoring the
urgent need for new treatments.
About Stargardt’s Disease
Stargardt’s macular degeneration is a form of juvenile macular
degeneration that affects vision in children and young adults
between the ages of six and 20, with a prevalence of approximately
one in 10,000 people in the United States. It is an orphan disease
and loss of vision is an inevitable aspect of SMD, with more than
half of the patients experiencing vision loss in the range of
20/200-20/400. Like dry AMD, it occurs as a result of damage to the
RPE layer and there are no treatments currently approved to prevent
or slow the vision loss associated with SMD.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20151106005964/en/
Investors:Westwicke PartnersJohn Woolford,
443-213-0506john.woolford@westwicke.comorPress:Russo PartnersDavid
Schull, 858-717-2310david.schull@russopartnersllc.com
Ocata Therapeutics, Inc. (NASDAQ:OCAT)
Historical Stock Chart
From Aug 2024 to Sep 2024
Ocata Therapeutics, Inc. (NASDAQ:OCAT)
Historical Stock Chart
From Sep 2023 to Sep 2024